short code it's doesn't matter. 3 three pages report. DOES NOT NEED REFERENCING STYLE
FINAL PROJECT DATA I. About the Data: The data is for 2016-17 NBA season. The NBA season starts in October and ended in June. The GSW (Golden State Warriors) won the NBA finals on June 12, 2017 by 4-1 in the best of 7-game series beating Cleveland Cavaliers. Note that there are two rows for each game. For example, the row 2 and row 24 are both for the same game which was played on October 26, 2016 between Miami and Orlando. The statistics provided in columns K through AB are for the team listed in Column A. Meaning, you will need both rows for each game to get team statistics for both teams. Also, the TeamScr (Column G) is the points scored by team listed in Column A. And, the OppScr (Column H) has the points scored by team listed in Column D. If you do not know the basketball game then I recommend watching a game or two to learn about the game and what the team statistics provided in the data represent. For a data analyst, it is quite routine to learn about the process/event for which data is being analyzed. II. About the Report You will need to submit a 3-page report and the program source code as two separate files. Both must be submitted in Moodle as pdf files. (a). The 3-page pdf report should have: i. Page 1: A one page summary of the overall findings. What did you find in the data which would be of interest to a basketball fan or to the NBA executives? ii. Page 2: A one-page summary for the New Orleans (Pelicans) fans. What worked and what did not for Pelicans? What are the keys to success for Pelicans? And, what are key characteristics when Pelicans lost? The data analytics needs to be more rigorous/informative than obvious statements like—make more shots, rebound well and do not turn the ball over! Just to give an example, a statement like “For home games, Pelicans won xx% of their games when they had yy more rebounds their opponents, whereas for road games….”. iii. The page 3 of the report would be used for reporting the fitting of regression models to predict the scores of both teams. The GameType (Column I) is 1 for regular-season games and 2 for the playoff games. Fit an appropriate regression model to predict the scores for the regular season games. Then use this regression model to predict the scores of the playoff games. In particular, use your fitted regression model to predict the scores of the five games which were played in NBA finals between Golden State Warriors and Cleveland Cavaliers. Also, report on theany changes between the regular season and playoff’s final series Golden State Warriors and Cleveland Cavaliers—did the teams get better or worse in finals? Justify with statistics. (b). The program code file (in pdf) must have comments to state what is being done. Remdesivir for the Treatment of Covid-19 — Preliminary Report T h e n e w e ngl a nd j o u r na l o f m e dic i n e n engl j med nejm.org 1 The authors’ full names, academic de- grees, and affiliations are listed in the Ap- pendix. Address reprint requests to Dr. Beigel at the National Institute of Allergy and Infectious Diseases, National Insti- tutes of Health, 5601 Fishers Ln., Rm. 7E60, MSC 9826, Rockville, MD 20892- 9826, or at jbeigel@ niaid . nih . gov. *A complete list of members of the ACTT-1 Study Group is provided in the Supplementary Appendix, available at NEJM.org. This article was published on May 22, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2007764 Copyright © 2020 Massachusetts Medical Society. BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coro- navirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection- control purposes only. RESULTS A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Pre- liminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received pla- cebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). the kaplan- meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% ci, 0.47 to 1.04). serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who un- derwent randomization (27.0%). conclusions remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with covid-19 and evidence of lower respiratory tract infection. (funded by the national institute of allergy and infectious diseases and others; acct-1 clinicaltrials.gov number, nct04280705.) a bs tr ac t remdesivir for the treatment of covid-19 — preliminary report j.h. beigel, k.m. tomashek, l.e. dodd, a.k. mehta, b.s. zingman, a.c. kalil, e. hohmann, h.y. chu, a. luetkemeyer, s. kline, d. lopez de castilla, r.w. finberg, k. dierberg, v. tapson, l. hsieh, t.f. patterson, r. paredes, d.a. sweeney, w.r. short, g. touloumi, d.c. lye, n. ohmagari, m. oh, g.m. ruiz-palacios, t. benfield, g. fätkenheuer, m.g. kortepeter, r.l. atmar, c.b. creech, j. lundgren, a.g. babiker, s. pett, j.d. neaton, t.h. burgess, t. bonnett, m. green, m. makowski, a. osinusi, s. nayak, and h.c. lane, for the actt-1 study group members* original article the new england journal of medicine downloaded from nejm.org on may 22, 2020. for personal use only. no other uses without permission. copyright © 2020 massachusetts medical society. all rights reserved. n engl j med nejm.org 2 t h e n e w e ngl a nd j o u r na l o f m e dic i n e a novel coronavirus, severe acute res piratory syndrome coronavirus 2 (sars-cov-2), was first identified in de- cember 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or covid-19.1 several therapeutic agents have been evaluated for the treatment of covid-19, but none have yet been shown to be efficacious.2,3 remdesivir (gs-5734), an inhibitor of the viral rna-dependent, rna polymerase with inhibitory activity against sars- cov and the middle east respiratory syndrome (mers-cov),4-7 was identified early as a promis- ing therapeutic candidate for covid-19 because of its ability to inhibit sars-cov-2 in vitro.8 in addition, in nonhuman primate studies, remdes- ivir initiated 12 hours after inoculation with mers-cov9,10 reduced lung virus levels and lung damage. to evaluate the clinical efficacy and safety of putative investigational therapeutic agents among hospitalized adults with laboratory-confirmed covid-19, we designed an adaptive platform to rapidly conduct a series of phase 3, randomized, double-blind, placebo-controlled trials. here, we describe the preliminary results of the first stage of the adaptive covid-19 treatment trial (actt-1), in which we evaluated treatment with remdesivir as compared with placebo. me thods design enrollment for actt-1 began on february 21, 2020, and ended on april 19, 2020. there were 60 trial sites and 13 subsites in the united states (45 sites), denmark (8), the united kingdom (5), greece (4), germany (3), korea (2), mexico (2), spain (2), japan (1), and singapore (1). eligible patients were randomly assigned in a 1:1 ratio to receive either remdesivir or placebo. randomiza- tion was stratified by study site and disease se- verity at enrollment (see the supplementary ap- pendix, available with the full text of this article at nejm.org, for details about stratification crite- ria). remdesivir was administered intravenously as a 200-mg loading dose on day 1, followed by a 100-mg maintenance dose administered daily on days 2 through 10 or until hospital discharge or death. a matching placebo was administered according to the same schedule and in the same volume as the active drug. a normal saline pla- cebo was used at the european sites and at some non-european sites owing to a shortage of match- ing placebo; the infusions were masked with an opaque bag and tubing covers to maintain blind- ing. all patients received supportive care accord- ing to the standard of care for the trial site hos- pital. if a hospital had a written policy or guideline for use of other treatments for covid-19, patients could receive those treatments. in the absence of a written policy or guideline, other experimental treatment or off-label use of mar- keted medications intended as specific treat- ment for covid-19 were prohibited from day 1 through day 29 (though such medications could have been used before enrollment in this trial). the trial protocol was approved by the insti- tutional review board at each site (or by a cen- tralized institutional review board as applicable) and was overseen by an independent data and safety monitoring board. informed consent was obtained from each patient or from the patient’s legally authorized representative if the patient was unable to provide consent. full details of the trial design, conduct, oversight, and analyses can be the="" kaplan-="" meier="" estimates="" of="" mortality="" by="" 14="" days="" were="" 7.1%="" with="" remdesivir="" and="" 11.9%="" with="" placebo="" (hazard="" ratio="" for="" death,="" 0.70;="" 95%="" ci,="" 0.47="" to="" 1.04).="" serious="" adverse="" events="" were="" reported="" for="" 114="" of="" the="" 541="" patients="" in="" the="" remdesivir="" group="" who="" underwent="" randomization="" (21.1%)="" and="" 141="" of="" the="" 522="" patients="" in="" the="" placebo="" group="" who="" un-="" derwent="" randomization="" (27.0%).="" conclusions="" remdesivir="" was="" superior="" to="" placebo="" in="" shortening="" the="" time="" to="" recovery="" in="" adults="" hospitalized="" with="" covid-19="" and="" evidence="" of="" lower="" respiratory="" tract="" infection.="" (funded="" by="" the="" national="" institute="" of="" allergy="" and="" infectious="" diseases="" and="" others;="" acct-1="" clinicaltrials.gov="" number,="" nct04280705.)="" a="" bs="" tr="" ac="" t="" remdesivir="" for="" the="" treatment="" of="" covid-19="" —="" preliminary="" report="" j.h.="" beigel,="" k.m.="" tomashek,="" l.e.="" dodd,="" a.k.="" mehta,="" b.s.="" zingman,="" a.c.="" kalil,="" e.="" hohmann,="" h.y.="" chu,="" a.="" luetkemeyer,="" s.="" kline,="" d.="" lopez="" de="" castilla,="" r.w.="" finberg,="" k.="" dierberg,="" v.="" tapson,="" l.="" hsieh,="" t.f.="" patterson,="" r.="" paredes,="" d.a.="" sweeney,="" w.r.="" short,="" g.="" touloumi,="" d.c.="" lye,="" n.="" ohmagari,="" m.="" oh,="" g.m.="" ruiz-palacios,="" t.="" benfield,="" g.="" fätkenheuer,="" m.g.="" kortepeter,="" r.l.="" atmar,="" c.b.="" creech,="" j.="" lundgren,="" a.g.="" babiker,="" s.="" pett,="" j.d.="" neaton,="" t.h.="" burgess,="" t.="" bonnett,="" m.="" green,="" m.="" makowski,="" a.="" osinusi,="" s.="" nayak,="" and="" h.c.="" lane,="" for="" the="" actt-1="" study="" group="" members*="" original="" article="" the="" new="" england="" journal="" of="" medicine="" downloaded="" from="" nejm.org="" on="" may="" 22,="" 2020.="" for="" personal="" use="" only.="" no="" other="" uses="" without="" permission.="" copyright="" ©="" 2020="" massachusetts="" medical="" society.="" all="" rights="" reserved.="" n="" engl="" j="" med="" nejm.org="" 2="" t="" h="" e="" n="" e="" w="" e="" ngl="" a="" nd="" j="" o="" u="" r="" na="" l="" o="" f="" m="" e="" dic="" i="" n="" e="" a="" novel="" coronavirus,="" severe="" acute="" res="" piratory="" syndrome="" coronavirus="" 2="" (sars-cov-2),="" was="" first="" identified="" in="" de-="" cember="" 2019="" as="" the="" cause="" of="" a="" respiratory="" illness="" designated="" coronavirus="" disease="" 2019,="" or="" covid-19.1="" several="" therapeutic="" agents="" have="" been="" evaluated="" for="" the="" treatment="" of="" covid-19,="" but="" none="" have="" yet="" been="" shown="" to="" be="" efficacious.2,3="" remdesivir="" (gs-5734),="" an="" inhibitor="" of="" the="" viral="" rna-dependent,="" rna="" polymerase="" with="" inhibitory="" activity="" against="" sars-="" cov="" and="" the="" middle="" east="" respiratory="" syndrome="" (mers-cov),4-7="" was="" identified="" early="" as="" a="" promis-="" ing="" therapeutic="" candidate="" for="" covid-19="" because="" of="" its="" ability="" to="" inhibit="" sars-cov-2="" in="" vitro.8="" in="" addition,="" in="" nonhuman="" primate="" studies,="" remdes-="" ivir="" initiated="" 12="" hours="" after="" inoculation="" with="" mers-cov9,10="" reduced="" lung="" virus="" levels="" and="" lung="" damage.="" to="" evaluate="" the="" clinical="" efficacy="" and="" safety="" of="" putative="" investigational="" therapeutic="" agents="" among="" hospitalized="" adults="" with="" laboratory-confirmed="" covid-19,="" we="" designed="" an="" adaptive="" platform="" to="" rapidly="" conduct="" a="" series="" of="" phase="" 3,="" randomized,="" double-blind,="" placebo-controlled="" trials.="" here,="" we="" describe="" the="" preliminary="" results="" of="" the="" first="" stage="" of="" the="" adaptive="" covid-19="" treatment="" trial="" (actt-1),="" in="" which="" we="" evaluated="" treatment="" with="" remdesivir="" as="" compared="" with="" placebo.="" me="" thods="" design="" enrollment="" for="" actt-1="" began="" on="" february="" 21,="" 2020,="" and="" ended="" on="" april="" 19,="" 2020.="" there="" were="" 60="" trial="" sites="" and="" 13="" subsites="" in="" the="" united="" states="" (45="" sites),="" denmark="" (8),="" the="" united="" kingdom="" (5),="" greece="" (4),="" germany="" (3),="" korea="" (2),="" mexico="" (2),="" spain="" (2),="" japan="" (1),="" and="" singapore="" (1).="" eligible="" patients="" were="" randomly="" assigned="" in="" a="" 1:1="" ratio="" to="" receive="" either="" remdesivir="" or="" placebo.="" randomiza-="" tion="" was="" stratified="" by="" study="" site="" and="" disease="" se-="" verity="" at="" enrollment="" (see="" the="" supplementary="" ap-="" pendix,="" available="" with="" the="" full="" text="" of="" this="" article="" at="" nejm.org,="" for="" details="" about="" stratification="" crite-="" ria).="" remdesivir="" was="" administered="" intravenously="" as="" a="" 200-mg="" loading="" dose="" on="" day="" 1,="" followed="" by="" a="" 100-mg="" maintenance="" dose="" administered="" daily="" on="" days="" 2="" through="" 10="" or="" until="" hospital="" discharge="" or="" death.="" a="" matching="" placebo="" was="" administered="" according="" to="" the="" same="" schedule="" and="" in="" the="" same="" volume="" as="" the="" active="" drug.="" a="" normal="" saline="" pla-="" cebo="" was="" used="" at="" the="" european="" sites="" and="" at="" some="" non-european="" sites="" owing="" to="" a="" shortage="" of="" match-="" ing="" placebo;="" the="" infusions="" were="" masked="" with="" an="" opaque="" bag="" and="" tubing="" covers="" to="" maintain="" blind-="" ing.="" all="" patients="" received="" supportive="" care="" accord-="" ing="" to="" the="" standard="" of="" care="" for="" the="" trial="" site="" hos-="" pital.="" if="" a="" hospital="" had="" a="" written="" policy="" or="" guideline="" for="" use="" of="" other="" treatments="" for="" covid-19,="" patients="" could="" receive="" those="" treatments.="" in="" the="" absence="" of="" a="" written="" policy="" or="" guideline,="" other="" experimental="" treatment="" or="" off-label="" use="" of="" mar-="" keted="" medications="" intended="" as="" specific="" treat-="" ment="" for="" covid-19="" were="" prohibited="" from="" day="" 1="" through="" day="" 29="" (though="" such="" medications="" could="" have="" been="" used="" before="" enrollment="" in="" this="" trial).="" the="" trial="" protocol="" was="" approved="" by="" the="" insti-="" tutional="" review="" board="" at="" each="" site="" (or="" by="" a="" cen-="" tralized="" institutional="" review="" board="" as="" applicable)="" and="" was="" overseen="" by="" an="" independent="" data="" and="" safety="" monitoring="" board.="" informed="" consent="" was="" obtained="" from="" each="" patient="" or="" from="" the="" patient’s="" legally="" authorized="" representative="" if="" the="" patient="" was="" unable="" to="" provide="" consent.="" full="" details="" of="" the="" trial="" design,="" conduct,="" oversight,="" and="" analyses="" can="">